Indole 3-acetate and response to therapy in borderline resectable or locally advanced pancreatic cancer
- PMID: 39759130
- PMCID: PMC11695226
- DOI: 10.3389/fonc.2024.1488749
Indole 3-acetate and response to therapy in borderline resectable or locally advanced pancreatic cancer
Abstract
Background/aims: It was recently reported that a higher concentration of the bacterially produced metabolite indole 3-acetate (3-IAA) in blood was linked to a better response to chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Here, we aimed to extend these observations to patients diagnosed with non-metastatic PDAC.
Method: We measured circulating 3-IAA in samples from a prospective population-based cohort of 124 patients with borderline resectable or locally advanced PDAC, collected before initiating neoadjuvant chemotherapy. The majority (61%) of the patients were treated with FOLFIRINOX. We used univariable and multivariable Cox proportional hazards regression to estimate the association between pre-treatment 3-IAA and overall survival.
Results: The median serum 3-IAA concentration before chemotherapy was 290 (interquartile range 203-417) ng/mL. The unadjusted hazard ratio (HR) for pre-treatment log2(3-IAA) was 0.93, 95% confidence interval (CI) [0.74-1.16], p=0.52. When adjusting for age, ECOG, CA19-9 and tumor classification, the HR for log2(3-IAA) was 0.87, 95% CI [0.68-1.12], p=0.28.
Conclusion: Our findings suggest that the potentiating effect of 3-IAA observed in metastatic PDAC undergoing chemotherapy may not translate to borderline resectable or locally advanced PDAC. We recommend additional clinical validation of 3-IAA's predictive value in different categories of PDAC before implementation attempts in human studies are initiated.
Keywords: 3-IAA; biomarkers; chemotherapy - oncology; indole 3-acetic acid; indoles; microbiome; pancreatic adenocarcinoma.
Copyright © 2024 Braadland, Farnes, Kure, Yaqub, McCann, Ueland, Labori and Hov.
Conflict of interest statement
Authors AM and PU were employed by the company BEVITAL AS. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
-
- Larsen IK, Johannesen TB, Seglem AH, Hestad JJ, Jakobsen E, Mangrud OM, et al. . Cancer in Norway 2023. In: Larsen IK, editor. Cancer Registry of Norway (Kreftregisteret; ) (2024). M. BR.T. E., L. S.
LinkOut - more resources
Full Text Sources
